{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:15:59Z","timestamp":1793103359105,"version":"4.5.0"},"reference-count":133,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,24]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Inflammatory bowel diseases [IBD] exhibit intestinal and systemic manifestations. Nonalcoholic fatty liver disease [NAFLD] is a common co-existing condition, possibly contributing to the cardio-metabolic burden and overall morbidity. \u0395merging therapeutic choices of biologic agents have modified the clinical course of IBD; however, their impact on IBD-associated NAFLD has not been extensively evaluated. The prevalence of NAFLD varies among IBD patients, but it appears higher than in the general population in the majority of quality studies. In terms of pathogenetic and risk factors of NAFLD, they may vary with IBD activity. Dysbiosis, mucosal damage, and cytokine release have been implicated in the pathogenesis during the relapses, whereas metabolic risk factors seem to play a dominant role during the remissions of IBD. Considering biologics, although quality data are scarce, agents suppressing tumour necrosis factor may offer potential benefits in IBD-associated NAFLD, whereas anti-integrins do not appear to confer any therapeutic advantage.<\/jats:p><jats:p>In conclusion, IBD-associated NAFLD possibly follows two different patterns, one manifested during the relapses and one during the remissions of IBD. Some, but not all, biologics may benefit NAFLD in patients with IBD. Further mechanistic and prospective cohort studies are warranted to illuminate the effects of various biologics on NAFLD.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjab212","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T12:17:37Z","timestamp":1637324257000},"page":"852-862","source":"Crossref","is-referenced-by-count":22,"title":["Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents"],"prefix":"10.1093","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3563-4973","authenticated-orcid":false,"given":"Apostolis","family":"Papaefthymiou","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, University Hospital of Larisa , Larisa, Thessaly , Greece"},{"name":"First Laboratory of Pharmacology, Aristotle University of Thessaloniki , Thessaloniki, Macedonia , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Potamianos","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital of Larisa , Larisa, Thessaly , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Goulas","sequence":"additional","affiliation":[{"name":"First Laboratory of Pharmacology, Aristotle University of Thessaloniki , Thessaloniki, Macedonia , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Doulberis","sequence":"additional","affiliation":[{"name":"First Laboratory of Pharmacology, Aristotle University of Thessaloniki , Thessaloniki, Macedonia , Greece"},{"name":"Division of Gastroenterology and Hepatology, Medical University Department , Kantonsspital Aarau, Aarau , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6459-5136","authenticated-orcid":false,"given":"Jannis","family":"Kountouras","sequence":"additional","affiliation":[{"name":"Second Medical Clinic, Ippokration Hospital, Aristotle University of Thessaloniki , Thessaloniki, Macedonia , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-4042","authenticated-orcid":false,"given":"Stergios A","family":"Polyzos","sequence":"additional","affiliation":[{"name":"First Laboratory of Pharmacology, Aristotle University of Thessaloniki , Thessaloniki, Macedonia , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"2022062411310799300_CIT0001","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/gutjnl-2017-315568","article-title":"Natural disease course of Crohn\u2019s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study","volume":"68","author":"Burisch","year":"2019","journal-title":"Gut"},{"key":"2022062411310799300_CIT0002","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1007\/s10620-020-06424-x","article-title":"Extraintestinal manifestations in patients with inflammatory bowel disease: study based on the ENEIDA Registry","volume":"66","author":"Algaba","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2022062411310799300_CIT0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.12794","article-title":"Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease","volume":"40","author":"Gizard","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2022062411310799300_CIT0004","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/liv.13265","article-title":"Hepatic manifestations of inflammatory bowel diseases","volume":"37","author":"Restellini","year":"2017","journal-title":"Liver Int"},{"key":"2022062411310799300_CIT0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.arcmed.2020.11.010","article-title":"Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease","volume":"52","author":"Makri","year":"2021","journal-title":"Arch Med Res"},{"key":"2022062411310799300_CIT0006","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","article-title":"Epidemiology and natural history of non-alcoholic fatty liver disease","volume":"65","author":"Fazel","year":"2016","journal-title":"Metabolism"},{"key":"2022062411310799300_CIT0007","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3109\/00365521.2014.921326","article-title":"National trends and inpatient outcomes of inflammatory bowel disease patients with concomitant chronic liver disease","volume":"49","author":"Nguyen","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"2022062411310799300_CIT0008","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/ibd\/izy200","article-title":"Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases: a cohort study using transient elastography","volume":"25","author":"Saroli Palumbo","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0009","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"2022062411310799300_CIT0010","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1097\/MIB.0000000000000832","article-title":"Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease","volume":"22","author":"Bessissow","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0011","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1002\/ibd.21585","article-title":"Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease","volume":"17","author":"Long","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0012","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1007\/s10620-017-4766-9","article-title":"Hepatic complications of anorexia nervosa","volume":"62","author":"Rosen","year":"2017","journal-title":"Dig Dis Sci"},{"key":"2022062411310799300_CIT0013","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2008.05.055","article-title":"Acute liver cell damage in patients with anorexia nervosa: a possible role of starvation-induced hepatocyte autophagy","volume":"135","author":"Rautou","year":"2008","journal-title":"Gastroenterology"},{"key":"2022062411310799300_CIT0014","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/MIB.0000000000001085","article-title":"Epidemiology and risk factors of nonalcoholic fatty liver disease among patients with inflammatory bowel disease","volume":"23","author":"Glassner","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0015","doi-asserted-by":"crossref","first-page":"154203","DOI":"10.1016\/j.metabol.2020.154203","article-title":"Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis","volume":"111","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"2022062411310799300_CIT0016","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0017","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/apt.15692","article-title":"Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease","volume":"51","author":"Piovani","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2022062411310799300_CIT0018","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.3748\/wjg.v22.i34.7727","article-title":"Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: a review article","volume":"22","author":"Chao","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2022062411310799300_CIT0019","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/j.crohns.2012.10.015","article-title":"Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"7","author":"Sourianarayanane","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2022062411310799300_CIT0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ibd.21669","article-title":"Changing shape of disease: nonalcoholic fatty liver disease in Crohn\u2019s disease","volume":"18","author":"McGowan","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0021","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.cgh.2019.02.045","article-title":"Crohn\u2019s disease is associated with an increased prevalence of nonalcoholic fatty liver disease: a cross-sectional study using magnetic resonance proton density fat fraction mapping","volume":"17","author":"McHenry","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022062411310799300_CIT0022","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12876-019-0967-3","article-title":"Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: a referral center study","volume":"19","author":"Fousekis","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"2022062411310799300_CIT0023","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.metabol.2013.10.010","article-title":"Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease","volume":"63","author":"Polyzos","year":"2014","journal-title":"Metabolism"},{"key":"2022062411310799300_CIT0024","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1665-2681(19)31615-1","article-title":"Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis","volume":"9","author":"Yamamoto-Furusho","year":"2010","journal-title":"Ann Hepatol"},{"key":"2022062411310799300_CIT0025","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1093\/ibd\/izz043","article-title":"Systematic review with meta-analysis: epidemiology of nonalcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"25","author":"Zou","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0026","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/ibd\/izaa189","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"27","author":"Lin","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0027","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ajg.2012.06.005","article-title":"Hepatobiliary disorders among na\u00efve patients with ulcerative colitis in Upper Egypt","volume":"13","author":"Morsy","year":"2012","journal-title":"Arab J Gastroenterol"},{"key":"2022062411310799300_CIT0028","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1093\/ecco-jcc\/jjx002.448","article-title":"Fatty liver assessment in inflammatory bowel disease patients using controlled attenuation parameter","volume":"11","author":"Balaban","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2022062411310799300_CIT0029","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MIB.0000000000000569","article-title":"PNPLA3 148M carriers with inflammatory bowel diseases have higher susceptibility to hepatic steatosis and higher liver enzymes","volume":"22","author":"Mancina","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0030","doi-asserted-by":"crossref","first-page":"e0206450","DOI":"10.1371\/journal.pone.0206450","article-title":"Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: a case-control study","volume":"13","author":"Adams","year":"2018","journal-title":"PLoS One"},{"key":"2022062411310799300_CIT0031","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022062411310799300_CIT0032","first-page":"10633","article-title":"High incidence of non-alcoholic fatty liver disease in patients with Crohn\u2019s disease but not ulcerative colitis","volume":"10","author":"Li","year":"2017","journal-title":"Int J Clin Exp Pathol"},{"key":"2022062411310799300_CIT0033","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.3748\/wjg.v26.i46.7367","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: a cross-sectional and longitudinal analysis","volume":"26","author":"Hoffmann","year":"2020","journal-title":"World J Gastroenterol"},{"key":"2022062411310799300_CIT0034","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.3748\/wjg.v25.i37.5676","article-title":"Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: beyond the natural history","volume":"25","author":"Magr\u00ec","year":"2019","journal-title":"World J Gastroenterol"},{"key":"2022062411310799300_CIT0035","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1007\/s10620-020-06588-6","article-title":"Nonalcoholic fatty liver disease is common in IBD patients; however progression to hepatic fibrosis by noninvasive markers is rare","volume":"66","author":"Ritaccio","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2022062411310799300_CIT0036","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/hepr.12828","article-title":"Significance of non-alcoholic fatty liver disease in Crohn\u2019s disease: a retrospective cohort study","volume":"47","author":"Sagami","year":"2017","journal-title":"Hepatol Res"},{"key":"2022062411310799300_CIT0037","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/ibd\/izy051","article-title":"Nonalcoholic fatty liver disease in inflammatory bowel disease: prevalence and risk factors","volume":"24","author":"Principi","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0038","doi-asserted-by":"crossref","first-page":"e0252286","DOI":"10.1371\/journal.pone.0252286","article-title":"Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: a Taiwanese retrospective cohort study","volume":"16","author":"Yen","year":"2021","journal-title":"PLoS One"},{"key":"2022062411310799300_CIT0039","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1159\/000506938","article-title":"Sarcopenia is a new risk factor of nonalcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"38","author":"Kang","year":"2020","journal-title":"Dig Dis"},{"key":"2022062411310799300_CIT0040","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.3390\/nu13082772","article-title":"The other side of malnutrition in inflammatory bowel disease [IBD]: non-alcoholic fatty liver disease","volume":"13","author":"Gibiino","year":"2021","journal-title":"Nutrients"},{"key":"2022062411310799300_CIT0041","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s42000-018-0049-x","article-title":"Sarcopenic obesity","volume":"17","author":"Polyzos","year":"2018","journal-title":"Hormones"},{"key":"2022062411310799300_CIT0042","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"key":"2022062411310799300_CIT0043","first-page":"463","article-title":"High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy","volume":"32","author":"Likhitsup","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"2022062411310799300_CIT0044","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep.22399","article-title":"Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis","volume":"48","author":"Maher","year":"2008","journal-title":"Hepatology"},{"key":"2022062411310799300_CIT0045","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MEG.0000000000001541","article-title":"Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"32","author":"Wijarnpreecha","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2022062411310799300_CIT0046","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41419-017-0124-2","article-title":"Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease","volume":"9","author":"Sartini","year":"2018","journal-title":"Cell Death Dis"},{"key":"2022062411310799300_CIT0047","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s10620-017-4495-0","article-title":"Intestinal inflammation does not predict nonalcoholic fatty liver disease severity in inflammatory bowel disease patients","volume":"62","author":"Carr","year":"2017","journal-title":"Dig Dis Sci"},{"key":"2022062411310799300_CIT0048","first-page":"5818","article-title":"Multifaceted pathogenesis of liver steatosis in inflammatory bowel disease: a systematic review","volume":"25","author":"Spagnuolo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2022062411310799300_CIT0049","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/ibd\/izy128","article-title":"IRGM gene variants modify the relationship between visceral adipose tissue and NAFLD in patients with Crohn\u2019s disease","volume":"24","author":"Simon","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2017.09.008","article-title":"Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease","volume":"69","author":"Bosch","year":"2017","journal-title":"Hum Pathol"},{"key":"2022062411310799300_CIT0051","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"key":"2022062411310799300_CIT0052","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.metabol.2015.11.006","article-title":"Adipokines in nonalcoholic fatty liver disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"2022062411310799300_CIT0053","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/ibd.21336","article-title":"Liver diseases associated with anti-tumor necrosis factor-alpha [TNF-\u03b1] use for inflammatory bowel disease","volume":"17","author":"Coffin","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0054","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jhep.2011.02.035","article-title":"DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH","volume":"55","author":"G\u00e4bele","year":"2011","journal-title":"J Hepatol"},{"key":"2022062411310799300_CIT0055","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1111\/jgh.15631","article-title":"Circulating tumor necrosis factor-\u03b1 levels in non-alcoholic fatty liver disease: a systematic review and a meta-analysis","volume":"36","author":"Potoupni","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"2022062411310799300_CIT0056","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1194\/jlr.R600021-JLR200","article-title":"The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk","volume":"48","author":"Popa","year":"2007","journal-title":"J Lipid Res"},{"key":"2022062411310799300_CIT0057","first-page":"2714","article-title":"Nonalcoholic steatohepatitis: what we know in the new millennium","volume":"97","author":"Harrison","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"2022062411310799300_CIT0058","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1053\/gast.2002.32995","article-title":"Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat","volume":"122","author":"Ikejima","year":"2002","journal-title":"Gastroenterology"},{"key":"2022062411310799300_CIT0059","doi-asserted-by":"crossref","first-page":"e0181039","DOI":"10.1371\/journal.pone.0181039","article-title":"An update on psoriasis and metabolic syndrome: a meta-analysis of observational studies","volume":"12","author":"Singh","year":"2017","journal-title":"PLoS One"},{"key":"2022062411310799300_CIT0060","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/hep.21782","article-title":"Suppressor of cytokine signaling 3 [SOCS3] expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy","volume":"46","author":"Persico","year":"2007","journal-title":"Hepatology"},{"key":"2022062411310799300_CIT0061","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/gut.2005.071118","article-title":"Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice","volume":"55","author":"Tomita","year":"2006","journal-title":"Gut"},{"key":"2022062411310799300_CIT0062","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1126\/science.271.5249.665","article-title":"IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance","volume":"271","author":"Hotamisligil","year":"1996","journal-title":"Science"},{"key":"2022062411310799300_CIT0063","doi-asserted-by":"crossref","first-page":"92","DOI":"10.23736\/S0391-1977.16.02563-3","article-title":"Adipose tissue, obesity and non-alcoholic fatty liver disease","volume":"42","author":"Polyzos","year":"2017","journal-title":"Minerva Endocrinol"},{"key":"2022062411310799300_CIT0064","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1463-1326.2009.01176.x","article-title":"The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease","volume":"12","author":"Polyzos","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"2022062411310799300_CIT0065","first-page":"127; author reply 128","article-title":"The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease","volume":"13","author":"Polyzos","year":"2009","journal-title":"Hippokratia"},{"key":"2022062411310799300_CIT0066","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/MIB.0000000000000209","article-title":"Metabolic inflammation in inflammatory bowel disease: crosstalk between adipose tissue and bowel","volume":"21","author":"Gon\u00e7alves","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0067","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.metabol.2014.10.012","article-title":"Leptin in nonalcoholic fatty liver disease: a narrative review","volume":"64","author":"Polyzos","year":"2015","journal-title":"Metabolism"},{"key":"2022062411310799300_CIT0068","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11010-019-03581-0","article-title":"Apelin promotes hepatic fibrosis through ERK signaling in LX-2 cells","volume":"460","author":"Wang","year":"2019","journal-title":"Mol Cell Biochem"},{"key":"2022062411310799300_CIT0069","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/eji.1830250216","article-title":"Alpha E beta 7 and alpha 4 beta 7 integrins associated with intraepithelial and mucosal homing, are expressed on macrophages","volume":"25","author":"Tiisala","year":"1995","journal-title":"Eur J Immunol"},{"key":"2022062411310799300_CIT0070","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jhep.2017.02.001","article-title":"\u03b27-Integrin and MAdCAM-1 play opposing roles during the development of non-alcoholic steatohepatitis","volume":"66","author":"Drescher","year":"2017","journal-title":"J Hepatol"},{"key":"2022062411310799300_CIT0071","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jcmgh.2020.12.003","article-title":"MAdCAM-1\/\u03b14\u03b27 integrin-mediated lymphocyte\/endothelium interactions exacerbate acute immune-mediated hepatitis in mice","volume":"11","author":"Schippers","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2022062411310799300_CIT0072","doi-asserted-by":"crossref","first-page":"534","DOI":"10.21614\/chirurgia.113.4.534","article-title":"The role of beta-7 integrin and carbonic anhydrase IX in predicting the occurrence of de novo nonalcoholic fatty liver disease in liver transplant recipients","volume":"113","author":"Ester","year":"2018","journal-title":"Chirurgia"},{"key":"2022062411310799300_CIT0073","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/2050640617708953","article-title":"The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease","volume":"6","author":"Torres","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"2022062411310799300_CIT0074","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94416","article-title":"Microbiota, cirrhosis, and the emerging oral-gut-liver axis","volume":"2","author":"Acharya","year":"2017","journal-title":"JCI Insight"},{"key":"2022062411310799300_CIT0075","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.cgh.2018.07.004","article-title":"Obesity is independently associated with higher annual burden and costs of hospitalization in patients with inflammatory bowel diseases","volume":"17","author":"Nguyen","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022062411310799300_CIT0076","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1467-789X.2010.00797.x","article-title":"Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes?","volume":"12","author":"Diamant","year":"2011","journal-title":"Obes Rev"},{"key":"2022062411310799300_CIT0077","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrgastro.2010.172","article-title":"The role of the gut microbiota in nonalcoholic fatty liver disease","volume":"7","author":"Abu-Shanab","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022062411310799300_CIT0078","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nature05414","article-title":"An obesity-associated gut microbiome with increased capacity for energy harvest","volume":"444","author":"Turnbaugh","year":"2006","journal-title":"Nature"},{"key":"2022062411310799300_CIT0079","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1038\/emm.2017.282","article-title":"Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions","volume":"50","author":"Chelakkot","year":"2018","journal-title":"Exp Mol Med"},{"key":"2022062411310799300_CIT0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12876-014-0189-7","article-title":"Intestinal permeability \u2013 a new target for disease prevention and therapy","volume":"14","author":"Bischoff","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"2022062411310799300_CIT0081","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00394-017-1524-x","article-title":"Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis","volume":"57","author":"de Faria Ghetti","year":"2018","journal-title":"Eur J Nutr"},{"key":"2022062411310799300_CIT0082","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrgastro.2012.21","article-title":"Microbiota: dysbiosis driven by inflammasome deficiency exacerbates hepatic steatosis and governs rate of NAFLD progression","volume":"9","author":"Wood","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022062411310799300_CIT0083","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.immuni.2010.03.003","article-title":"The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis","volume":"32","author":"Zaki","year":"2010","journal-title":"Immunity"},{"key":"2022062411310799300_CIT0084","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/ibd.21478","article-title":"NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis","volume":"17","author":"Hirota","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity","volume":"482","author":"Henao-Mejia","year":"2012","journal-title":"Nature"},{"key":"2022062411310799300_CIT0086","doi-asserted-by":"crossref","first-page":"17568","DOI":"10.1038\/s41598-017-17187-3","article-title":"Author Correction: lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD","volume":"7","author":"Pierantonelli","year":"2017","journal-title":"Sci Rep"},{"key":"2022062411310799300_CIT0087","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/MEG.0000000000001144","article-title":"Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis","volume":"30","author":"Lapumnuaypol","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2022062411310799300_CIT0088","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1093\/ibd\/izaa286","article-title":"Vedolizumab-associated drug-induced liver injury: a case series","volume":"27","author":"Honap","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2022062411310799300_CIT0089","article-title":"Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment","author":"Bj\u00f6rnsson","year":"2021","journal-title":"J Hepatol"},{"key":"2022062411310799300_CIT0090","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2016","journal-title":"Gut"},{"key":"2022062411310799300_CIT0091","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016. Part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2022062411310799300_CIT0092","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2022062411310799300_CIT0093","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"2022062411310799300_CIT0094","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody [adalimumab] in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"2022062411310799300_CIT0095","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"2022062411310799300_CIT0096","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JIR.S165330","article-title":"Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives","volume":"11","author":"Rawla","year":"2018","journal-title":"J Inflamm Res"},{"key":"2022062411310799300_CIT0097","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/jhep.2003.50048","article-title":"Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease","volume":"37","author":"Li","year":"2003","journal-title":"Hepatology"},{"key":"2022062411310799300_CIT0098","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1677\/JOE-07-0234","article-title":"Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet","volume":"194","author":"Barbuio","year":"2007","journal-title":"J Endocrinol"},{"key":"2022062411310799300_CIT0099","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10753-007-9053-z","article-title":"The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet","volume":"31","author":"Koca","year":"2008","journal-title":"Inflammation"},{"key":"2022062411310799300_CIT0100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/hep.21313","article-title":"Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob\/ob mice","volume":"44","author":"Garc\u00eda-Ruiz","year":"2006","journal-title":"Hepatology"},{"key":"2022062411310799300_CIT0101","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MCG.0b013e3181ec5c66","article-title":"The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature","volume":"45","author":"Polyzos","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"2022062411310799300_CIT0102","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-0043-118666","article-title":"Pivotal role of TNF-\u03b1 in the development and progression of nonalcoholic fatty liver disease in a murine model","volume":"50","author":"Kakino","year":"2018","journal-title":"Horm Metab Res"},{"key":"2022062411310799300_CIT0103","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.mce.2014.01.014","article-title":"Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit","volume":"384","author":"Vignozzi","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"2022062411310799300_CIT0104","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/ijd.12706","article-title":"Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-\u03b1 inhibitors: results of a retrospective analysis","volume":"54","author":"Campanati","year":"2015","journal-title":"Int J Dermatol"},{"key":"2022062411310799300_CIT0105","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/hep.510260621","article-title":"Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat","volume":"26","author":"Iimuro","year":"1997","journal-title":"Hepatology"},{"key":"2022062411310799300_CIT0106","doi-asserted-by":"crossref","first-page":"8760","DOI":"10.3748\/wjg.v22.i39.8760","article-title":"Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis","volume":"22","author":"Ilan","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2022062411310799300_CIT0107","first-page":"1","article-title":"Tumor necrosis factor inhibitors for rheumatoid arthritis","volume":"48","author":"Jones","year":"1999","journal-title":"Bull Rheum Dis"},{"key":"2022062411310799300_CIT0108","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3899\/jrheum.111391","article-title":"Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-\u03b1 blockers","volume":"39","author":"Di Minno","year":"2012","journal-title":"J Rheumatol"},{"key":"2022062411310799300_CIT0109","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1136\/ard.2009.116194","article-title":"Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study","volume":"69","author":"Seitz","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2022062411310799300_CIT0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10238-014-0323-4","article-title":"Metabolic syndrome and chronic arthritis: effects of anti-TNF-\u03b1 therapy","volume":"15","author":"Maruotti","year":"2015","journal-title":"Clin Exp Med"},{"key":"2022062411310799300_CIT0111","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10067-013-2369-1","article-title":"Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients","volume":"33","author":"Costa","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2022062411310799300_CIT0112","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2022062411310799300_CIT0113","first-page":"2440","article-title":"Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab","volume":"33","author":"Spanakis","year":"2006","journal-title":"J Rheumatol"},{"key":"2022062411310799300_CIT0114","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13075-015-0559-8","article-title":"Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis","volume":"17","author":"Chen","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2022062411310799300_CIT0115","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1590\/S0482-50042013000500013","article-title":"Lipid profile and anti-TNF-\u03b1 use","volume":"53","author":"Ferraz Filho","year":"2013","journal-title":"Rev Bras Reumatol"},{"key":"2022062411310799300_CIT0116","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2011-201148","article-title":"Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis","volume":"71","author":"Da\u00efen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022062411310799300_CIT0117","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MEG.0b013e328325d42b","article-title":"Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease","volume":"21","author":"Koutroubakis","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2022062411310799300_CIT0118","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2022062411310799300_CIT0119","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"2022062411310799300_CIT0120","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/gut.2007.122168","article-title":"Immunology of the gut and liver: a love\/hate relationship","volume":"57","author":"Adams","year":"2008","journal-title":"Gut"},{"key":"2022062411310799300_CIT0121","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1053\/jhep.2001.24231","article-title":"MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium [MAdCAM-1 in chronic inflammatory liver disease]","volume":"33","author":"Grant","year":"2001","journal-title":"Hepatology"},{"key":"2022062411310799300_CIT0122","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/00042737-199907000-00015","article-title":"Immunohistochemical analysis of inflammation in primary sclerosing cholangitis","volume":"11","author":"Ponsioen","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2022062411310799300_CIT0123","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.2337\/diacare.46.10.1542","article-title":"Involvement of beta 7 integrin and mucosal addressin cell adhesion molecule-1 [MAdCAM-1] in the development of diabetes in obese diabetic mice","volume":"46","author":"Yang","year":"1997","journal-title":"Diabetes"},{"key":"2022062411310799300_CIT0124","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jaut.2010.04.002","article-title":"Alpha4beta7 integrin\/MAdCAM-1 adhesion pathway is crucial for B cell migration into pancreatic lymph nodes in nonobese diabetic mice","volume":"35","author":"Xu","year":"2010","journal-title":"J Autoimmun"},{"key":"2022062411310799300_CIT0125","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.4049\/jimmunol.166.2.1300","article-title":"TNF-alpha-induced expression of adhesion molecules in the liver is under the control of TNFR1 \u2013 relevance for concanavalin A-induced hepatitis","volume":"166","author":"Wolf","year":"2001","journal-title":"J Immunol"},{"key":"2022062411310799300_CIT0126","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2015.12.017","article-title":"Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study [Psoriasis Longitudinal Assessment and Registry (PSOLAR)]","volume":"74","author":"Strober","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2022062411310799300_CIT0127","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2022062411310799300_CIT0128","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2022062411310799300_CIT0129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.biomaterials.2015.05.042","article-title":"Shifts in oxidation states of cerium oxide nanoparticles detected inside intact hydrated cells and organelles","volume":"62","author":"Szymanski","year":"2015","journal-title":"Biomaterials"},{"key":"2022062411310799300_CIT0130","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/annrheumdis-2013-204101","article-title":"Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects","volume":"74","author":"Krieckaert","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022062411310799300_CIT0131","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"2022062411310799300_CIT0132","doi-asserted-by":"crossref","first-page":"154413","DOI":"10.1016\/j.metabol.2020.154413","article-title":"Commentary: nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name","volume":"113","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"2022062411310799300_CIT0133","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1080\/14656566.2016.1225727","article-title":"Emerging and future therapies for nonalcoholic steatohepatitis in adults","volume":"17","author":"Mintziori","year":"2016","journal-title":"Expert Opin Pharmacother"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjab212\/42004805\/jjab212.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/5\/852\/44245573\/jjab212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/5\/852\/44245573\/jjab212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T21:09:55Z","timestamp":1673816995000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/5\/852\/6433262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":133,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,11,22]]},"published-print":{"date-parts":[[2022,6,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab212","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,11,22]]}}}